New York State Teachers Retirement System Has $45.98 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• The New York State Teachers Retirement System holds a stake of approximately $45.98 million in Regeneron Pharmaceuticals, after decreasing its position by 4.5% in the second quarter.
• Regeneron recently reported quarterly earnings of $12.89 per share, exceeding analysts' expectations of $8.43, with revenues hitting $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%.

New York State Teachers Retirement System decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 87,579 shares of the biopharmaceutical company's stock after selling 4,128 shares during the period. New York State Teachers Retirement System owned about 0.08% of Regeneron Pharmaceuticals worth $45,979,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Sepio Capital LP raised its holdings in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after acquiring an additional 842 shares during the period. Founders Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock worth $4,344,000 after purchasing an additional 538 shares during the period. PGGM Investments increased its holdings in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock worth $44,308,000 after purchasing an additional 51,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after purchasing an additional 955 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $569.17 on Friday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $60.33 billion, a price-to-earnings ratio of 14.34, a PEG ratio of 1.85 and a beta of 0.31. The firm's 50 day moving average is $574.34 and its 200-day moving average is $563.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,013.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $11.56 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. Weiss Ratings restated a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Finally, Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a research report on Friday, October 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $817.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.